The broad spectrum of activity of tinengotinib, in particular, dual inhibition of JAK-STAT and FGFR signaling and blockade of lineage plasticity, may be a factor in the responders as efficacy assessments observed in patients with HR-positive/HER2-negative breast cancer, TNBC, and metastatic CRPC (mCRPC), among others, who did not have FGFR alterations at study entry. This evidence concerns the gene SOAT1 and breast carcinoma.